

UK DRUG FILE

MICROMEDEX

NATIONAL DRUG FILES



# A single source for detailed evidence and UK-approved drug information

How to save pharmacists' precious time, cross-referencing numerous sources of information ...

A question of trust in the evidence at hand when making critical patient safety decisions ...

Difficult choices about which drug information resources to keep as the NHS faces further cuts ...

**Micromedex has the answer.**

For more than 40 years, over 5,000 hospitals and healthcare institutions in 85 countries have trusted Micromedex. Now there's no need to go anywhere else to find UK SmPCs and information about medicines licensed for use in the UK — side-by-side with the comprehensive evidence you've always relied upon. The new UK Drug File delivers UK-approved dose, use, and possible side-effects information, in the familiar, consistent Micromedex format.

**No gaps, no inconsistencies. Just clear evidence and fast answers.**

In-house editorial staff ensures quality and consistency. An ongoing review of the world's medical journals by our editorial team of 90+ healthcare professionals — physicians, clinical pharmacists, medical librarians, and an expert in research methodology — includes evaluation and synthesis of more than half a million articles annually to provide appropriate treatment recommendations. We scrutinize the full body of evidence so you can be confident your decisions are based on the most complete, relevant, and consistent information available.

Acetaminophen [your search: Paracetamol]  
Intravenous, Oral, Rectal

View detailed document • | View summary document • | Jump to 1572 other search results

| MICROMEDEX DRUG SUMMARY INFORMATION   |  |  |
|---|--|--|
| <ul style="list-style-type: none"> <li>Adult Dosing</li> <li>Pediatric Dosing</li> <li>Dose Adjustments</li> <li>ICD-10 Labels/Indications</li> <li>Non-FDA Labeled Indications</li> <li>Black Box Warning</li> <li>Oral Route</li> <li>Contraindications</li> <li>Precautions</li> <li>Pregnancy Category</li> </ul> | <ul style="list-style-type: none"> <li>Breast Feeding</li> <li>Drug Interactions (single)</li> <li>Adverse Effects - Common</li> <li>Adverse Effects - Serious</li> <li>IV Compatibility (single)</li> <li>Drug Images (US)</li> <li>US Trade Names</li> <li>Class</li> <li>Regulatory Status</li> </ul> | <ul style="list-style-type: none"> <li>Generic Availability</li> <li>Mechanism of Action/Pharmacokinetics</li> <li>Administration/Route/Route</li> <li>How Supplied</li> <li>Toxicology - Clinical Effects</li> <li>Toxicology - Treatment</li> <li>Toxicology - Range of Toxicity</li> <li>Clinical Teaching</li> <li>References</li> </ul> |

| OTHER INFORMATION  |  |  |
|--|--|--|
| <b>MARTINDALE</b>  | <b>INDEX NOMINUM</b>   | <b>IT-DIALOGO SUI FARMACI</b>  |
| Paracetamol  | Paracetamol (Racine)   | <ul style="list-style-type: none"> <li>ACETAMOL 10 ovule 300 mg</li> <li>ACETAMOL 10 sup 1 g</li> <li>ACETAMOL 16 cpr 481 g</li> <li>ACETAMOL 20 cpr 500 mg</li> </ul>   |
| <b>eMC SmPC (UK)</b>   | <b>FORB</b>  | <b>CONSUMER DRUG INFO</b>  |
| <ul style="list-style-type: none"> <li>Alvedon Suppositories 60, 120, 250 mg</li> <li>Anadin Paracetamol Tablets</li> <li>Boots Cold &amp; Flu Relief Powders Lemon Flavour</li> <li>Boots Paracetamol 3 Months Plus 120 mg/5 ml Suspension</li> </ul> | <ul style="list-style-type: none"> <li>Children's Tylenol Metaxalen Chivavale Tablets</li> <li>Regular Strength Tylenol Tablets</li> </ul> | <ul style="list-style-type: none"> <li>ACETAMINOPHEN (intravenous route) - 3-6461-g-MH-of-Aen</li> <li>ACETAMINOPHEN (oral route, Rectal route) - 3-6461-a-MH</li> </ul> |

| PRODUCT LOOKUP  |  |
|---|--|
| <ul style="list-style-type: none"> <li>Toxic Drug Acetaminophen</li> <li>Multidose Acetaminophen</li> <li>RED BOOK Online Acetaminophen</li> </ul>  | <b>DRUG IMAGES (US)</b><br><br>More Images • |
| <b>DRUG CONSULTS (12 results)</b><br><ul style="list-style-type: none"> <li>ACETAMINOPHEN PEDIATRIC DOSING CHART</li> <li>CAPISULES TABLETS THAT SHOULD NOT BE CRUSHED GUIDE</li> <li>COMPARATIVE DOSEAGE TABLE - ANALGETIC/DECONGESTANT</li> <li>ALTYMETAMIC COMBINATIONS</li> <li>COMPARATIVE DOSEAGE TABLE - EXPECTORANT COMBINATIONS</li> </ul> |  |
| <b>COMPARATIVE EFFICACY (45 results)</b><br><ul style="list-style-type: none"> <li>Acetaminophen</li> <li>Acetaminophen/Cocaine Phosphate</li> <li>Acetaminophen/Chlorzoxiprone/Aspirin/Ibuprofen/Ketorolac</li> <li>Acetaminophen/Hydrocodone Bitartrate</li> </ul>  |  |
| <b>MARTINDALE - OTHER INFO (1 result)</b><br><ul style="list-style-type: none"> <li>Analgesic Anti-inflammatory Drugs and Antipyretics</li> </ul>   |  |

*“With Micromedex,  
I’m sure to  
find what I’m  
looking for.”*

Beyond drug summaries and package insert data to deliver full evidence.

You’ll find unparalleled coverage of off-label drug use, mechanism of action, how side effects work in certain conditions, in-trial results, therapeutic use, and comparative data. Unlike other resources, Micromedex consistently provides in-line referencing and fully cited studies so you always have the complete picture. There’s no need to search multiple levels of content because our summary and in-depth content is linked, clinically consistent and accessible from a single screen.

Evidence ratings and recommendations take you closer to the answer.

Even for those complex, out-of-the-ordinary questions, we give you the context behind the evidence. We cover unique or controversial issues surrounding the drug or treatment. You’ll find no inconsistencies and no need to waste time reconciling conflicting information. Simple icons, unique evidence ratings and actionable recommendations help you make the critical decisions. Fast.

#### **Now with Micromedex you can:**

- Consult the eMC’s Summary of Product Characteristics
- Search on generic or trade names for dose and form
- View indications approved by the MHRA and EMA
- Save time with the information you need all in one place
- Search by any brand name from the main search box
- Find all EMA-approved drugs

#### **The complete picture:**

- Literature surveillance and evaluation by in-house editorial staff
- Complete, cited evidence to support off-label use decisions
- In-line referencing of the full body of evidence
- Strength of evidence and efficacy ratings; actionable recommendations
- More than just a drug summary or package insert
- The whole picture on which to make confident decisions



The National Institute of Health and Care Excellence (NICE) has accredited the process used by Truven Health Analytics to develop content used in its Micromedex Solutions. For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation)

## Can your drug information resources answer all these questions?

### Micromedex can.

- What's the licensed dose for this medicine here in the UK?
- What are the MHRA-approved indications for this therapy?
- What are the alternative forms for this drug?
- How should I prescribe this medicine?

1. NAME OF THE MEDICINAL PRODUCT  
2. QUALITATIVE AND QUANTITATIVE COMPOSITION  
3. PHARMACEUTICAL FORM  
4. CLINICAL PARTICULARS  
4.1 THERAPEUTIC INDICATIONS  
4.2 POSOLOGY AND METHOD OF ADMINISTRATION

**Panadol Capsules**  
United Kingdom Drug Information

1. NAME OF THE MEDICINAL PRODUCT

- Panadol / Paracetamol Capsules

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

- Each capsule contains Paracetamol Ph Eur 500.0 mg

3. PHARMACEUTICAL FORM

- Capsule

4. CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

- Panadol Capsules is a mild analgesic and antipyretic, and is recommended for the treatment of most painful and febrile conditions, for example, headache including migraine and tension headaches, toothache, backache, rheumatic and muscle pains, dysmenorrhoea, sore throat, and for relieving the fever, aches and pains of colds and flu.

4.2. POSOLOGY AND METHOD OF ADMINISTRATION

- How well would this drug therapy work for my patient, under these specific conditions?
- How strong is the evidence supporting use of this medicine in this way?
- What is the longest duration of this dose used in clinical trials?
- Is putting my patient on this regimen worth the risk of the side effects?
- How many patients were in this study, and were they similar to my patient?
- What was the clinical significance of the effects of this drug?

**Micromedex 2.0** | mobileMicromedex®

MY SUBSCRIPTION | MICROMEDEX GATEWAY | LOG OUT | HELP

Tools: Drug Interactions, Treata's™2 IV Compatibility, Drug Identification, Tox & Drug Product Lookup, Drug Comparison, RED BOOK Online®, Calculators, Formulary, CareNotes®, NeoFax® / Pediatrics

Enter one or more search terms SEARCH Example Searches

OVERVIEW  
DOSING INFORMATION  
PHARMACOKINETICS  
CAUTIONS  
CLINICAL APPLICATIONS  
REFERENCES

**BEVACIZUMAB**  
DRUGDEX® Evaluators OTHER SOURCES

CLINICAL APPLICATIONS

Age related macular degeneration, Secondary to choroidal neovascularization

1) Overview  
FDA Approval: Adult, no; Pediatric, no  
Efficacy: Adult, Evidence favors efficacy  
Recommendation: Adult, Class IIB  
Strength of Evidence: Adult, Category B  
See Drug Consult reference: RECOMMENDATION AND EVIDENCE RATINGS

2) Summary  
Administration of intravitreal bevacizumab has been associated with improved visual acuity [54][55][56][57][58][59], decreased central thickness [54][55][56][59], and decreased total macular volume [56] in patients with choroidal neovascularization secondary to age-related macular degeneration

There were no significant ocular side effects observed [59][60][54][55][56][57]; however, 4 occurrences of thromboembolic events were noted in one retrospective study [58]

3) Adult:  
a) Clinical Trials  
1) Patients with choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) treated with intravitreal bevacizumab experienced improved visual acuity and reduced retinal thickness in a retrospective study. Patients (n=51, mean age, 82 years (yr), range, 67 to 99 yr) with a baseline initial visual acuity of 20/30 (logMAR 1.2) or greater and subfoveal CNV from AMD received bevacizumab 1.25 mg intravitreally (injected through the pars plana into the vitreous cavity). Bevacizumab was given at one month intervals (in most cases) until there was no evidence of disease activity, although the schedule was determined by the treating physician. Photodynamic therapy with verteporfin (PDT) was allowed if the treating physician felt that treatment was failing to stabilize or improve vision or if there was evidence of persistent disease despite treatment. Additionally, some patients received topical antibiotics. Patients were evaluated initially by ophthalmic examinations using Early Treatment Diabetic Retinopathy Study (ET-DRS) charts, slit-lamp biomicroscopic examination of the anterior segment, and dilated fundusoscopic examination of the posterior pole and then monthly with optical coherence tomography (OCT) (if possible) or fluorescein angiography and/or clinical examination. The mean duration of follow-up in this study was 138 days (range, 48 to 222 days) and there were 176 bevacizumab injections given to a total of 84 eyes (mean number of injections per eye, 3.3; range 1 to 7 injections). Overall, visual acuity was significantly improved (p<0.01) from an initial mean of 20/125 (logMAR 0.8) to a final mean of 20/100 (log MAR 0.7), with 46 of 84 eyes (55%) experiencing no change or improvement of at least one line of vision, 12 of 84 eyes (14%) experiencing an improvement of 3 or more lines of vision, and 8 of 84 eyes (10%) experiencing worsening of at least one line of vision. The 36 of 84 eyes (43%) who had initial and follow-up OCT data demonstrated a significant mean decrease in central thickness at the end of follow-up of 127 micrometer (p less than 0.0001). Of patients who had cystic retinal thickening, subretinal fluid, or pigment epithelial detachment (PED) at baseline, 69%, 69%, and 67% (respectively) had resolution of the condition at the end of follow-up. There were no statistically significant differences in visual acuity (p=0.28) or OCT data (p=0.62) outcomes between previously treated patients (38 of 84 eyes (45%)) and treatment-naïve patients (16 of 84 eyes (20%)). Furthermore, there were no statistically significant differences in visual acuity (p=0.21) or OCT data (p=0.87) outcomes between eyes which received PDT (11 of 84 eyes (13%)) and eyes which received bevacizumab alone (43 of 84 eyes (51%)). No systemic (eg, hypertension, stroke, myocardial infarction) or ocular (eg, uveitis, infectious endophthalmitis, vitreous hemorrhage) adverse effects were reported in this study [58]

Strength of efficacy and evidence ratings

Fully cited studies

Study detail



## FOR MORE INFORMATION

To learn more, visit [truvenhealth.com](http://truvenhealth.com)  
or email us at [globalhealthcare@truvenhealth.com](mailto:globalhealthcare@truvenhealth.com)

### ABOUT TRUVEN HEALTH ANALYTICS

Truven Health Analytics delivers unbiased information, analytic tools, benchmarks, and services to the healthcare industry. Hospitals, government agencies, employers, health plans, clinicians, and life sciences companies have relied on us for more than 30 years. We combine our deep clinical, financial, and healthcare management expertise with innovative technology platforms and information assets to make healthcare better by collaborating with our customers to uncover and realize opportunities for improving quality, efficiency, and outcomes. With more than 2,000 employees, we have major offices in Ann Arbor, Michigan; Chicago; and Denver. Advantage Suite, Micromedex, ActionOI, MarketScan, and 100 Top Hospitals are registered trademarks or trademarks of Truven Health Analytics.

[truvenhealth.com](http://truvenhealth.com) | 1.800.525.9083

©2012 Truven Health Analytics Inc. All rights reserved. All other products names used herein are trademarks of their respective owners. INTL 11453 1012